Back to Search
Start Over
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
- Source :
- The Lancet. Respiratory medicine, 8 (5
- Publication Year :
- 2020
-
Abstract
- The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.<br />info:eu-repo/semantics/published
- Subjects :
- Diarrhea
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Indoles
Vital Capacity
Population
nintedanib, idiopathic pulmonary fibrosis
Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO
behavioral disciplines and activities
law.invention
03 medical and health sciences
chemistry.chemical_compound
Idiopathic pulmonary fibrosis
FEV1/FVC ratio
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
law
Internal medicine
nintedanib
medicine
Humans
030212 general & internal medicine
education
Protein Kinase Inhibitors
Idiopathic interstitial pneumonia
Aged
education.field_of_study
business.industry
Interstitial lung disease
Nausea
Middle Aged
respiratory system
Sciences bio-médicales et agricoles
medicine.disease
Idiopathic Pulmonary Fibrosis
respiratory tract diseases
body regions
030228 respiratory system
chemistry
Disease Progression
Female
Nintedanib
business
Hypersensitivity pneumonitis
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- The Lancet. Respiratory medicine, 8 (5
- Accession number :
- edsair.doi.dedup.....12fb103566afe883ea90e5352d7b9ae8